Jack Cuzick1, Jane Warwick, Elizabeth Pinney, Ruth M L Warren, Stephen W Duffy. 1. Cancer Research UK, Department of Epidemiology, Mathematics and Statistics, Wolfson Institute of Preventive Medicine, Queen Mary College, University of London, London, UK. jack.cuzick@cancer.org.uk
Abstract
BACKGROUND: Although mammographic breast density is associated with the risk of breast cancer and is influenced by hormone levels, the effects of tamoxifen on breast density in healthy women and whether tamoxifen-induced density changes are associated with breast cancer risk are unclear. We investigated mammographic breast density in healthy women with an increased risk of breast cancer at baseline and during 54 months of tamoxifen treatment. METHODS: Mammograms were reviewed from 818 breast cancer-free women (388 in the tamoxifen group and 430 in the placebo group) at high risk for breast cancer, from the International Breast Cancer Intervention Study I, a trial of tamoxifen for breast cancer prevention. Breast density measurements, at baseline and during treatment, were obtained at 12- to 18-month intervals. Multivariable analysis was used to assess associations with breast density. All statistical tests were two-sided. RESULTS:Breast density at baseline was similar in placebo (42.6%, 95% confidence interval [CI] = 39.6% to 45.6%) and tamoxifen (41.9%, 95% CI = 38.8% to 45.0%) groups. The main determinants of breast density at baseline were age, menopausal status, body mass index, and previous atypical hyperplasia. A greater density reduction in the tamoxifen group (7.9%, 95% CI = 6.9% to 8.9%) than in the placebo group (3.5%, 95% CI = 2.7% to 4.3%) was apparent within 18 months of treatment (P<.001); the reduction in density continued until 54 months of treatment. After 54 months of tamoxifen treatment, breast density was 28.2% (decrease from baseline = 13.7%, 95% CI = 12.3% to 15.1%; P<.001) in the tamoxifen group and 35.3% (decrease from baseline = 7.3%, 95% CI = 6.1% to 8.4%; P<.001) in the placebo group. The tamoxifen-associated density reduction was apparent in all subgroups, but there was a statistically significant interaction with age. In women aged 45 years or younger at entry, the net reduction with tamoxifen was 13.4% (95% CI = 8.6% to 18.1%), whereas in women older than 55 years, it was 1.1% (95% CI = -3.0% to 5.1%). CONCLUSION:Tamoxifen treatment was associated with reduction in breast density, most of which occurred during the first 18 months of treatment.
RCT Entities:
BACKGROUND: Although mammographic breast density is associated with the risk of breast cancer and is influenced by hormone levels, the effects of tamoxifen on breast density in healthy women and whether tamoxifen-induced density changes are associated with breast cancer risk are unclear. We investigated mammographic breast density in healthy women with an increased risk of breast cancer at baseline and during 54 months of tamoxifen treatment. METHODS: Mammograms were reviewed from 818 breast cancer-free women (388 in the tamoxifen group and 430 in the placebo group) at high risk for breast cancer, from the International Breast Cancer Intervention Study I, a trial of tamoxifen for breast cancer prevention. Breast density measurements, at baseline and during treatment, were obtained at 12- to 18-month intervals. Multivariable analysis was used to assess associations with breast density. All statistical tests were two-sided. RESULTS: Breast density at baseline was similar in placebo (42.6%, 95% confidence interval [CI] = 39.6% to 45.6%) and tamoxifen (41.9%, 95% CI = 38.8% to 45.0%) groups. The main determinants of breast density at baseline were age, menopausal status, body mass index, and previous atypical hyperplasia. A greater density reduction in the tamoxifen group (7.9%, 95% CI = 6.9% to 8.9%) than in the placebo group (3.5%, 95% CI = 2.7% to 4.3%) was apparent within 18 months of treatment (P<.001); the reduction in density continued until 54 months of treatment. After 54 months of tamoxifen treatment, breast density was 28.2% (decrease from baseline = 13.7%, 95% CI = 12.3% to 15.1%; P<.001) in the tamoxifen group and 35.3% (decrease from baseline = 7.3%, 95% CI = 6.1% to 8.4%; P<.001) in the placebo group. The tamoxifen-associated density reduction was apparent in all subgroups, but there was a statistically significant interaction with age. In women aged 45 years or younger at entry, the net reduction with tamoxifen was 13.4% (95% CI = 8.6% to 18.1%), whereas in women older than 55 years, it was 1.1% (95% CI = -3.0% to 5.1%). CONCLUSION:Tamoxifen treatment was associated with reduction in breast density, most of which occurred during the first 18 months of treatment.
Authors: Celine M Vachon; Hironobu Sasano; Karthik Ghosh; Kathleen R Brandt; David A Watson; Carol Reynolds; Wilma L Lingle; Paul E Goss; Rong Li; Sarah E Aiyar; Christopher G Scott; V Shane Pankratz; Richard J Santen; James N Ingle Journal: Breast Cancer Res Treat Date: 2010-06-05 Impact factor: 4.872
Authors: Norman F Boyd; Lisa J Martin; Michael Bronskill; Martin J Yaffe; Neb Duric; Salomon Minkin Journal: J Natl Cancer Inst Date: 2010-07-08 Impact factor: 13.506
Authors: Anieta M Sieuwerts; Giuseppina De Napoli; Anne van Galen; Helenius J Kloosterboer; Vanja de Weerd; Hong Zhang; John W M Martens; John A Foekens; Christian De Geyter Journal: Mol Oncol Date: 2011-09-16 Impact factor: 6.603
Authors: Carol J Fabian; Bruce F Kimler; Carola M Zalles; Jennifer R Klemp; Brian K Petroff; Qamar J Khan; Priyanka Sharma; Kenneth D R Setchell; Xueheng Zhao; Teresa A Phillips; Trina Metheny; Jennifer R Hughes; Hung-Wen Yeh; Karen A Johnson Journal: Cancer Prev Res (Phila) Date: 2010-08-19
Authors: Karla Kerlikowske; Andrea J Cook; Diana S M Buist; Steve R Cummings; Celine Vachon; Pamela Vacek; Diana L Miglioretti Journal: J Clin Oncol Date: 2010-07-19 Impact factor: 44.544
Authors: Katherine D Crew; Garnet L Anderson; Dawn L Hershman; Mary Beth Terry; Parisa Tehranifar; Danika L Lew; Monica Yee; Eric A Brown; Sebastien S Kairouz; Nafisa Kuwajerwala; Therese Bevers; John E Doster; Corrine Zarwan; Laura Kruper; Lori M Minasian; Leslie Ford; Banu Arun; Marian Neuhouser; Gary E Goodman; Powel H Brown Journal: Cancer Prev Res (Phila) Date: 2019-05-28
Authors: Anna H Wu; Darcy Spicer; Agustin Garcia; Chiu-Chen Tseng; Linda Hovanessian-Larsen; Pulin Sheth; Sue Ellen Martin; Debra Hawes; Christy Russell; Heather MacDonald; Debu Tripathy; Min-Ying Su; Giske Ursin; Malcolm C Pike Journal: Cancer Prev Res (Phila) Date: 2015-08-14
Authors: Christy G Woolcott; Kerry S Courneya; Norman F Boyd; Martin J Yaffe; Tim Terry; Anne McTiernan; Rollin Brant; Rachel Ballard-Barbash; Melinda L Irwin; Charlotte A Jones; Sony Brar; Kristin L Campbell; Margaret L McNeely; Kristina H Karvinen; Christine M Friedenreich Journal: Cancer Epidemiol Biomarkers Prev Date: 2010-03-23 Impact factor: 4.254
Authors: John J Heine; Michael J Carston; Christopher G Scott; Kathleen R Brandt; Fang-Fang Wu; Vernon Shane Pankratz; Thomas A Sellers; Celine M Vachon Journal: Cancer Epidemiol Biomarkers Prev Date: 2008-11 Impact factor: 4.254